-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 26, 2021, the World Health Organization (WHO) defined the new coronavirus variant B.
1.
1.
529, which is currently causing widespread global epidemics, as the fifth "variant of concern" (VOC) and named it Omic Rong (Omicron) mutant
.
The Omicron variant is the most mutated variant of the new coronavirus to date, and its spike protein (S protein) contains more than 30 amino acid mutations
.
Studies have shown that the Omicron variant has a high degree of immune evasion, which significantly reduces the protective efficacy of existing vaccines and antibodies
.
The research and development of a new vaccine for the Omicron variant is imminent, and the United States and the European Union have successively launched corresponding research plans
.
On February 14, 2022, the Qin Chengfeng team of the Academy of Military Medical Research of the Academy of Military Sciences and Suzhou Aibo Biotechnology Co.
, Ltd.
jointly published a report on Cell Research entitled: Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant Research paper [1]
.
The study used the mRNA-LNP technology platform of Aibo Biotechnology with independent intellectual property rights, targeting the receptor binding region (RBD) of the new crown Omicron mutant, and successfully developed an mRNA specific for Omicron mutant.
vaccine
.
Prior to this, Qin Chengfeng's team cooperated with Aibo to publish papers in Cell and Signal Transduction and Targeted Therapy journals [2, 3], and developed a thermostable new coronavirus mRNA vaccine - ARCoV
.
On January 24, 2022, the Phase I clinical trial data of ARCoV was published in the journal The Lancet Microbe [4], which confirmed the good safety and immunogenicity of this mRNA vaccine
.
And it can be stable for a long time (at least 6 months) at normal refrigerator temperature (2-8℃)
.
ARCoV is currently undergoing clinical phase III trials overseas
.
In this Cell Research paper, the research team first analyzed the cross-neutralization ability of Omicron in two-dose ARCoV vaccine population (n=11), and found that although most people (72.
7%) were still able to neutralize in vivo Omicron variant, but the level of neutralizing antibodies against Omicron was significantly reduced compared to the prototype strain
.
Interestingly, in the mouse model, the third dose of ARCoV booster immunization can significantly stimulate the production of 2019-nCoV neutralizing antibodies, and the neutralizing titers against the prototype strain and Omicron are both above 17,000
.
The research team further optimized the design of the coding sequence of Omicron RBD, and identified the two most efficient mRNAs from 18 candidate mRNAs through in vitro and in vivo expression screening.
The mRNA-LNP was completed using the exact same technical route as the first-generation vaccine ARCoV.
The samples were prepared and named ARCoV-Omicron
.
The results of mouse immunogenicity showed that two doses of ARCoV-Omicron vaccine could rapidly induce the production of high levels of neutralizing antibodies against Omicron 7 days after immunization of mice
.
It is particularly worth mentioning that the ARCoV-Omicron vaccine took only 32 days from sequence design to obtaining the first batch of mouse immunogenicity results, which once again demonstrated the rapid response capability of the mRNA vaccine technology platform
.
It is reported that the vaccine is also the world's first mRNA vaccine against Omicron that has been validated in animal tests and officially published.
.
At present, the ARCoV-Omicron vaccine has completed the production of GMP-level clinical samples and is applying for clinical trials
.
Researcher Qin Chengfeng of the Academy of Military Medical Sciences of the Academy of Military Sciences and Dr.
InBev from Suzhou Aibo Company are the corresponding authors of the paper.
Doctoral students Zhang Nana, Zhang Rongrong, master students Zhang Yifei and Xiong Xiaochuan of the Academy of Military Medicine of the Academy of Military Sciences, and Dr.
Ji Kai of Suzhou Aibo Company are tied for the first place.
an author
.
Zhou Hangyu, associate researcher at Suzhou Institute of Systems Medicine, made important contributions to this paper
.
Paper link: 1.
https:// https://doi.
org/10.
1016/j.
cell.
2020.
07.
0243.
https:// .
com/articles/s41392-021-00861-44.
https://doi.
org/10.
1016/S2666-5247(21)00280-9 "Bioworld" recently launched the "mRNA Technology" column, with weekly interpretation and introduction The latest research progress and reviews in the field of mRNA, as well as related startup company reports and interviews
.
We have also established a professional mRNA exchange group, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.
Open reprint welcome to forward to Moments and WeChat groups
1.
1.
529, which is currently causing widespread global epidemics, as the fifth "variant of concern" (VOC) and named it Omic Rong (Omicron) mutant
.
The Omicron variant is the most mutated variant of the new coronavirus to date, and its spike protein (S protein) contains more than 30 amino acid mutations
.
Studies have shown that the Omicron variant has a high degree of immune evasion, which significantly reduces the protective efficacy of existing vaccines and antibodies
.
The research and development of a new vaccine for the Omicron variant is imminent, and the United States and the European Union have successively launched corresponding research plans
.
On February 14, 2022, the Qin Chengfeng team of the Academy of Military Medical Research of the Academy of Military Sciences and Suzhou Aibo Biotechnology Co.
, Ltd.
jointly published a report on Cell Research entitled: Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant Research paper [1]
.
The study used the mRNA-LNP technology platform of Aibo Biotechnology with independent intellectual property rights, targeting the receptor binding region (RBD) of the new crown Omicron mutant, and successfully developed an mRNA specific for Omicron mutant.
vaccine
.
Prior to this, Qin Chengfeng's team cooperated with Aibo to publish papers in Cell and Signal Transduction and Targeted Therapy journals [2, 3], and developed a thermostable new coronavirus mRNA vaccine - ARCoV
.
On January 24, 2022, the Phase I clinical trial data of ARCoV was published in the journal The Lancet Microbe [4], which confirmed the good safety and immunogenicity of this mRNA vaccine
.
And it can be stable for a long time (at least 6 months) at normal refrigerator temperature (2-8℃)
.
ARCoV is currently undergoing clinical phase III trials overseas
.
In this Cell Research paper, the research team first analyzed the cross-neutralization ability of Omicron in two-dose ARCoV vaccine population (n=11), and found that although most people (72.
7%) were still able to neutralize in vivo Omicron variant, but the level of neutralizing antibodies against Omicron was significantly reduced compared to the prototype strain
.
Interestingly, in the mouse model, the third dose of ARCoV booster immunization can significantly stimulate the production of 2019-nCoV neutralizing antibodies, and the neutralizing titers against the prototype strain and Omicron are both above 17,000
.
The research team further optimized the design of the coding sequence of Omicron RBD, and identified the two most efficient mRNAs from 18 candidate mRNAs through in vitro and in vivo expression screening.
The mRNA-LNP was completed using the exact same technical route as the first-generation vaccine ARCoV.
The samples were prepared and named ARCoV-Omicron
.
The results of mouse immunogenicity showed that two doses of ARCoV-Omicron vaccine could rapidly induce the production of high levels of neutralizing antibodies against Omicron 7 days after immunization of mice
.
It is particularly worth mentioning that the ARCoV-Omicron vaccine took only 32 days from sequence design to obtaining the first batch of mouse immunogenicity results, which once again demonstrated the rapid response capability of the mRNA vaccine technology platform
.
It is reported that the vaccine is also the world's first mRNA vaccine against Omicron that has been validated in animal tests and officially published.
.
At present, the ARCoV-Omicron vaccine has completed the production of GMP-level clinical samples and is applying for clinical trials
.
Researcher Qin Chengfeng of the Academy of Military Medical Sciences of the Academy of Military Sciences and Dr.
InBev from Suzhou Aibo Company are the corresponding authors of the paper.
Doctoral students Zhang Nana, Zhang Rongrong, master students Zhang Yifei and Xiong Xiaochuan of the Academy of Military Medicine of the Academy of Military Sciences, and Dr.
Ji Kai of Suzhou Aibo Company are tied for the first place.
an author
.
Zhou Hangyu, associate researcher at Suzhou Institute of Systems Medicine, made important contributions to this paper
.
Paper link: 1.
https:// https://doi.
org/10.
1016/j.
cell.
2020.
07.
0243.
https:// .
com/articles/s41392-021-00861-44.
https://doi.
org/10.
1016/S2666-5247(21)00280-9 "Bioworld" recently launched the "mRNA Technology" column, with weekly interpretation and introduction The latest research progress and reviews in the field of mRNA, as well as related startup company reports and interviews
.
We have also established a professional mRNA exchange group, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.
Open reprint welcome to forward to Moments and WeChat groups
